Key Investor Signals
Closed €500,000 financing led by Angels
Biotasmart announced €500,000 in financing in February 2026, led by Angels with Dacsa Group and individual investors. ENISA also provided support for its expansion in professional health channels.
Reached first customers and over 50 users
Biotasmart gained its first customers in November 2024 and exceeded 50 users in its first commercial year, selling microbiome interpretation through health and nutrition professionals.
Won Best Longevity Pitch at the 2026 forum
Biotasmart won the Best Longevity Pitch Award at the Longevity World Forum in Madrid, earning strategic support from Banco Sabadell BStartup10 and Longevity Zone.
Other Positive Signals
- Selected as one of six startups for Lilly Spain's 11th Emprende inHealth programme, providing six months of mentoring from Lilly professionals.
Team
Olga Carbonell
Founder & CEO
- Led Vicky Foods’ healthy-food business unit in 2022–2023, gaining experience in product development, commercial planning and customer relationships.
- Managed commercial reporting and sales analysis at Vicky Foods from 2019 to 2022, using dashboards to track customer and assortment performance.
- Worked in supply-chain operations at Refresco from 2015 to 2017, covering purchasing, inventory, production planning and new-product launches.
María Gómez Romero
Co-founder & CPO
- Coordinated the CSIC computational-biology Junior Hub from 2024 and co-founded a mentoring initiative for early-career bioinformaticians.
- Conducted plant molecular-biology research at the UPV–CSIC institute with a Spanish Ministry of Education collaboration scholarship.
- Trained in biotechnology at the Polytechnic University of Valencia and studied bioinformatics at master’s level at the University of Valencia.
Product
Biotasmart coordinates sample collection, sequencing by a specialist laboratory and in-house interpretation through a professional platform. Its non-diagnostic tests describe gut or vaginal microbial composition and guide nutrition discussions, with reports returned in three to four weeks.
Gut microbiome test options
The Essential Test uses 16S sequencing to describe bacterial groups and provide food recommendations. The Advanced Test uses shotgun metagenomics for species-level analysis, functional profiles and guidance on prebiotics, probiotics and supplements.
Vaginal microbiome analysis
A swab-based shotgun metagenomics test identifies microbial species and classifies the vaginal community. The report is designed for discussion with a professional in women’s health, including fertility and menopause care.
Interpreted reports and patient records
Professionals access patient histories and detailed reports through a dashboard, while patients receive a plain-language version. Findings are prioritized into nutritional recommendations, and Biotasmart trains clinic teams to use the workflow.
Market Overview
Microbiome analysis is sold through sequencing services, test kits and interpretation platforms. Buyers range from research institutions to healthcare professionals and consumers seeking personalized nutrition. Clinics purchase interpreted tests to add a service that combines sample logistics, laboratory analysis and consultation support.
The broader analysis market remains research-led, while consumer and practitioner testing is a more specific commercial segment. Distribution combines direct online ordering with health-professional channels; providers compete on analytical depth, report clarity, turnaround and the usefulness of guidance during consultations.
Global revenue from microbiome analysis instruments, consumables and services was estimated at $1.4B in 2025.
Global microbiome analysis revenue is forecast to grow 12.4% annually from 2026 to 2033.
Research applications accounted for more than 62.5% of global microbiome analysis revenue in 2025.
Biotasmart lists its Essential gut test at €249 and Advanced gut test at €349 for direct purchase in Spain.
Comparable Outcomes
Microba
Microba provides gut microbiome testing services and uses its microbial datasets to develop therapeutic candidates, combining sequencing and analytical interpretation. Microba raised A$30M in its April 2022 Australian IPO. Its testing business served healthcare markets internationally, alongside a separate therapeutic-discovery programme.
Viome Life Sciences
Viome analyzes at-home biological samples to provide personalized nutrition recommendations and microbiome-related products, including a consumer gut-health test. Its August 2023 round included Khosla Ventures, Bold Capital and WRG Ventures. Viome also introduced its gut test in 200 CVS locations, adding national retail distribution.
Interested in More Startups Like Biotasmart?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.